Back to search
Campylobacter Jejuni Infection
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Campylobacter Jejuni Infection trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Campylobacter Jejuni Infection trials you may qualify forThis is a randomized, double-blind, dose-escalating, outpatient trial in a total of approximately 60 subjects, assigned to 3 cohorts (20 subjects per cohort). E…
Randomized, double-blind, placebo-controlled, single dose regimen study of LMN-101 followed by Campylobacter jejuni challenge. Subjects will initially, after do…
This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose levels of LMN-101. Healthy volunteers will take LMN-101 or placebo…
This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis fo…
The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hyd…
The principal research objective is to determine the impact of antibiotic use on the risk of developing long term bowel symptoms after infection with the germ C…
The goal of this research is to continue to develop a model of infection with Campylobacter jejuni, a bacterium that causes food and water-borne disease (mainly…
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
The primary objective of this study is to establish a human Campylobacter jejuni infection model with the following characteristics: 1. Safe application 1.…